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Abstract
Onodera’s prognostic nutritional index (PNI) is useful in predicting prognosis of various dis-
eases. But the usefulness of PNI in non-surgical patients has not been sufficiently proven
yet. In patients with mycobacterium avium complex pulmonary disease (MAC-PD), malnutri-
tion is an important factor that affects the quality of life and morbidity. Here, we aimed to
evaluate whether PNI is related with clinical outcomes in MAC-PD patients. We examined
663 patients diagnosed with MAC-PD between May 2005 and November 2017. PNI score
was calculated at the time of diagnosis and treatment initiation, and patients were divided
into malnutrition and non-malnutrition groups according to a cut-off PNI score of 45. As the
recommended duration of treatment for MAC-PD is 12 months following sputum conversion,
treatment duration less than 12 months was defined as treatment intolerance. Survivals
were compared with the log-rank test. Multivariate logistic regression and multivariate Cox
proportional hazards models were used to estimate the odds ratio (OR) and hazards ratio
(HR) for treatment intolerance and mortality, respectively. Of the 306 patients that received
treatment, 193 received treatment longer than 12 months. In the multivariable logistic
regression model, malnutrition at the time of treatment initiation was related with treatment
intolerance (OR: 2.559, 95% confidence interval [CI]: 1.414–4.634, P = 0.002). Patients in
the malnutrition group at the time of diagnosis exhibited lower survival (P<0.001) and malnu-
trition at the time of diagnosis was a significant risk for all-cause mortality (HR: 2.755, 95%
CI: 1.610–4.475, P<0.001). Malnutrition, as defined by PNI, is an independent predictor for
treatment intolerance and all-cause mortality in patients with MAC-PD.
Introduction
Malnutrition is generally associated with immune dysfunction and inflammatory processes,
[1] leading to diminished quality of life and increased mortality in patients with pulmonary
disease. [2, 3] Patients with malnutrition and limited respiratory reserves often have quantita-
tive and functional alterations in skeletal and respiratory muscles. [1, 4] Numerous indicators,
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including body composition, serum protein, and nutritional indices, such as nutritional risk
screening [5] and subjective global assessment, have been used as markers to reflect nutritional
status. [6] Among the various nutritional assessment tools, Onodera’s prognostic nutritional
index (PNI) [7] assesses serum albumin levels and total lymphocyte counts in the peripheral
blood. PNI was originally proposed to assess the perioperative nutritional status and surgical
risk in patients undergoing gastrointestinal surgery. Studies have shown PNI to be a versatile
prognostic tool for various malignancies. [8, 9] Compared to other nutritional indexes, PNI is
an index easily calculated using only serum albumin levels and lymphocyte counts and is
therefore easily assessable. But the usefulness of PNI in non-cancer medical patients has not
been sufficiently proven yet.
Nontuberculous mycobacterial pulmonary disease (NTM-PD) is becoming an increasingly
common diagnosis. [10–12] The most common etiology of NTM-PD is Mycobacterium avium
complex pulmonary disease (MAC-PD), [13] which is associated with an impaired quality of life
[14] and is difficult and costly to treat. [15] Recommended treatment regimens for MAC-PD
include macrolides, ethambutol, and rifampin. The American Thoracic Society (ATS) guide-
lines recommend a 12-month treatment period for MAC-PD following sputum conversion;
however, drug intolerance often limits successful therapy. [16] In one previous study, more
than one third of MAC-PD patients discontinued their medication because of drug intolerance,
and only 33% of MAC-PD patients who started treatment achieved culture conversion. [17]
Poor nutritional status indicated by various markers such as body mass index (BMI) and
low body fat is known to be an important factor for the pathogenesis and prognosis of
NTM-PD. [18–20] However, its clinical implications in the treatment of patients with
MAC-PD have not been evaluated as a composite value.
Therefore, in this study, we aimed to evaluate whether patients with malnutrition, as
defined by PNI, are at (1) higher odds of intolerance to treatment, (2) lower odds of achieving
culture conversion after treatment than non-malnutrition patients, and (3) higher risk of mor-
tality than non-malnutrition patients.
Materials and methods
Study design and population
This study was a retrospective cohort analysis conducted at a tertiary care hospital. The cohort
included patients diagnosed with MAC-PD between May 2005 and November 2017 (Fig 1).
Patients were selected from our retrospective NTM-PD registry based on the following criteria:
MAC-PD was confirmed according to the criteria by ATS. [15] Initially, 861 patients diag-
nosed with MAC-PD were included in the study. Patients were excluded if: (1) computed
tomography (CT) images at the time of diagnosis according to our institutional radiology data-
base were not available (n = 74); (2) clinical data, including age, height, body weight, smoking
history, laboratory results, and acid-fast bacilli (AFB) test results were unavailable (n = 114);
(3) there was a prior diagnosis of MAC-PD (n = 2); (4) there was a history of lung transplanta-
tion (n = 4); or (5) they were infected by hepatitis B virus (n = 2) or human immunodeficiency
virus (n = 2). In total, 663 patients were included in the analysis.
At the time of diagnosis, data on age, smoking history, laboratory test results, underlying
diseases, height and weight, radiographic findings, AFB test results, and symptoms were col-
lected from all patients. Age was categorized into two groups (age < 65 vs.� 65 years). AFB
test results were categorized into three groups (negative, ‘1+ and 2+’, and ‘3+ and 4+’). Radio-
graphic findings were categorized according to the presence of cavitary lesion on CT images.
After the diagnosis of MAC-PD, data regarding laboratory test results and antibiotic ther-
apy were collected from 306 patients who underwent antibiotic therapy. Laboratory test results
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at the time of treatment initiation were available from 278 patients, and culture conversion
data were available from 177 patients among 193 patients who underwent antibiotic therapy
for more than a year. As the recommended duration of treatment for MAC-PD is 12 months
following sputum conversion, treatment duration less than 12 months was defined as treat-
ment intolerance. Culture conversion was defined as the presence of at least three consecu-
tive negative mycobacterial cultures from respiratory samples collected at least 4 weeks
apart, in accord with the 2018 NTM-NET consensus statement [21]; Date of culture conver-
sion was established based on sampling date of the first negative culture. Follow-up data
including culture results and mortality were collected until October 2018. Mortality was esti-
mated based on the date of diagnosis to death or the last follow-up. The primary outcome
was all-cause mortality. Secondary outcomes were treatment intolerance and culture conver-
sion after antibiotic treatment.
Fig 1. Flow diagram of subjects in this study. List of Abbreviations: HBV, Hepatitis B Virus; HIV, Human Immunodeficiency Virus; MAC, Mycobacterium
avium complex; PNI, prognostic nutritional index.
https://doi.org/10.1371/journal.pone.0232714.g001
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Surrogate markers for evaluation of the nutritional status
The PNI score was calculated using the following formula at the time of MAC-PD diagnosis
and treatment initiation: 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in
the peripheral blood (/mm3). Patients were divided into malnutrition and non-malnutrition
groups according to a cut-off PNI score of 45. [22–24]
Statistical analysis
Chi-squared tests and student’s t-tests were used to compare categorical and continuous vari-
ables, respectively, between the two groups. Multivariate logistic regression models with back-
ward variable selection were used to estimate the odds ratios (ORs) for malnutrition and
culture conversion while controlling potential confounding factors. Survival was estimated
using the Kaplan–Meier method and compared using the log-rank test. Multivariate Cox pro-
portional hazards models were used to investigate relationships between clinical parameters
and mortality. Of the variables collected, serum albumin levels and lymphocyte counts were
not included in the multiple logistic regression models because they were included in the cal-
culation of PNI. Variables with a p-value (P)< 0.10, as determined by the log-rank test, were
included in the multivariate Cox proportional hazard ratio model. Variables included in all
multivariable analysis were tested for multicollinearity. An adjusted P< 0.05 was considered
statistically significant. All statistical analyses were performed using SPSS version 25.0 (SPSS
Inc., Chicago, IL, USA).
Ethics statement
This research protocol was approved by the Institutional Review Board / Ethics committee.
(Severance Hospital, Yonsei University Health System Institutional Review Board) The
requirement to obtain informed patient consent was waived because of the retrospective
nature of this study.
Results
Baseline characteristics
The baseline characteristics of participants with and without malnutrition at the time of diag-
nosis are shown in Table 1. Patients with malnutrition were older, predominantly male, and
had a lower BMI. The malnutrition group also had a higher proportion of participants with a
history of chronic kidney disease, cardiovascular, and malignancy than did the non-malnutri-
tion group. Based on the PNI calculations, malnutrition group had lower PNIs than the non-
malnutrition group (median: 38.3 vs. 50.0, P < 0.001). Those in the malnutrition group also
had a higher proportion of cavitary CT findings and positive AFB smear results. Symptomati-
cally, the malnutrition group reported more symptoms of dyspnea, fever, and general weak-
ness. Of 663 patients with MAC-PD, 63 died during the follow-up period. Malnutrition
patients showed significantly higher mortality rates during the follow-up (P< 0.001).
Variables related to treatment intolerance
Among 663 MAC-PD patients, 306 (46.1%) patients were treated for MAC-PD with multiple
antibiotics. To evaluate the factors related to treatment intolerance, these 306 patients were
stratified by treatment duration as follows (Table 2): 113 (36.9%) patients received treatment
for less than 12 months (shorter treatment group), and 193 (63.1%) patients received treatment
for longer than 12 months (longer treatment group). One third of patients did not stick to the
medication as scheduled.
PLOS ONE Mycobacterium avium complex lung disease and prognostic nutritional index
PLOS ONE | https://doi.org/10.1371/journal.pone.0232714 May 6, 2020 4 / 15
Most patients were treated with macrolides (97.4%), rifampin (97.7%), ethambutol (96.1%),
and aminoglycosides (13.7%). Drugs such as isoniazid (2.9%) and fluoroquinolones (3.6%)
were less frequently used. The mean treatment duration was 14.2 ± 10.1 months overall, with a
mean duration of 5.1 ± 3.9 and 19.5 ± 8.7 months in the shorter and longer treatment groups,
respectively. Patients in the shorter treatment group had lower PNI scores at either the time of
Table 1. Baseline clinical characteristics of 663 patients with Mycobacterium avium complex lung disease with or without malnutrition.
Variables All (n = 663) Non-malnutrition (n = 527) Malnutrition (136) P-value
Age, years 64.1 ± 11.8 62.5 ± 11.6 70.4 ± 10.8 <0.001
Age� 65 years 343 (51.7%) 243 (46.1%) 100 (73.5%) <0.001
Gender, male 292 (44.0%) 206 (39.1%) 86 (63.2%) <0.001
BMI, kg/m2 20.5 ± 3.3 20.8 ± 3.1 19.7 ± 3.7 <0.001
Smoking, pack-years 28.8 ± 23.2 28.5 ± 25.2 29.7 ± 15.8 0.787
Comorbidities
Hypertension 235 (35.4%) 184 (34.9%) 51 (37.5%) 0.615
Diabetes 97 (14.6%) 71 (13.5%) 26 (19.1%) 0.103
Chronic liver disease 43 (6.5%) 30 (5.7%) 13 (9.6%) 0.117
Chronic kidney disease 33 (5.0%) 22 (4.2%) 11 (8.1%) 0.075
Cardiovascular disease 93 (14.0%) 62 (11.8%) 31 (22.8%) 0.002
Malignancy 170 (25.6%) 130 (24.7%) 40 (29.4%) 0.271
Laboratory test
PNI� at time of diagnosis 50.0 ± 10.5 53.0 ± 9.3 38.3 ± 5.7 <0.001
Lymphocyte at time of diagnosis, 1000 cells/μL 1.87 ± 1.59 2.08 ± 1.72 1.09 ± 0.46 <0.001
Albumin at time of diagnosis, g/dL 4.1 ± 0.6 4.3 ± 0.4 3.3 ± 0.5 <0.001
PNI� at time of treatment initiation§ 49.1 ± 6.6 51.0 ± 4.5 42.1 ± 7.9 <0.001
Cavitary lesion on computed tomography 155 (23.4%) 113 (21.4%) 42 (30.9%) 0.023
AFB smear 0.011
Negative 569 (85.8%) 463 (87.9%) 106 (77.9%)
1+ or 2+ 69 (10.4%) 48 (9.1%) 21 (15.4%)
3+ or 4+ 25 (3.8%) 16 (3.0%) 9 (6.6%)
Symptoms
Cough 279 (42.1%) 216 (41.0%) 63 (46.3%) 0.284
Sputum 288 (43.4%) 231 (43.8%) 57 (41.9%) 0.699
Dyspnea 77 (11.6%) 42 (8.0%) 35 (25.7%) <0.001
Hemoptysis 107 (16.1%) 89 (16.9%) 18 (13.2%) 0.36
Fever 42 (6.3%) 20 (3.8%) 22 (16.2%) <0.001
Weakness 35 (5.3%) 11 (2.1%) 12 (8.8%) 0.001
Treatment started 306 (46.2%) 241 (45.7%) 65 (47.8%) 0.700
Treatment duration > 12 months 193 (29.1%) 165 (31.3%) 28 (20.6%) 0.015
Time from diagnosis to initiation of treatment, months 12.0 ± 21.3 13.1 ± 22.5 8.0 ± 15.3 0.096
Follow-up period, months 47.3 ± 33.5 50.1 ± 33.5 36.5 ± 31.3 <0.001
Culture conversion within a year after treatment‡ 161 / 239 (67.4%) 113 / 194 (68.6%) 28 / 45 (62.2%) 0.481
Death during follow-up 63 (9.5%) 34 (6.5%) 29 (21.3%) <0.001
Data are presented as number (%) for categorical variables and median (range) or mean ± standard deviation (SD) for continuous variables
List of Abbreviations: PNI, prognostic nutritional index; BMI, body mass index; AFB, acid-fast bacilli
�PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (/mm3)
§PNI data at time of treatment initiation were available for 287 patients
‡Culture conversion data within 1 year after treatment were available for 239 patients
https://doi.org/10.1371/journal.pone.0232714.t001
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Table 2. Basic characteristics of Mycobacterium avium complex lung disease patients who started treatment according to treatment tolerance (12 months).
Variables All (n = 306) Treatment longer than 12 months
(n = 193, 63.1%)
Treatment shorter than 12 months
(n = 113, 36.9%)
P-value
Age� 65 years 141 (46.1%) 85 (44.0%) 56 (49.6%) 0.406
Gender, male 132 (43.1%) 82 (42.5%) 50 (44.2%) 0.811
BMI, kg/m2 19.9 ± 3.3 19.8 ± 3.0 20.1 ± 3.8 0.433
Smoking, pack-years 34.4 ± 27.4 34.8 ± 25.7 33.9 ± 30.1 0.905
Comorbidities
Hypertension 92 (30.1%) 54 (28.0%) 38 (33.6%) 0.305
Diabetes 44 (14.4%) 26 (13.5%) 18 (15.9%) 0.613
Chronic liver disease 24 (7.8%) 13 (6.7%) 11 (9.7%) 0.382
Chronic kidney disease 12 (3.9%) 7 (3.6%) 5 (4.4%) 0.765
Cardiovascular disease 39 (12.7%) 23 (11.9%) 16 (14.2%) 0.597
Malignancy 71 (23.2%) 48 (24.9%) 23 (20.4%) 0.402
Laboratory test
PNI� at time of diagnosis 49.8 ± 9.0 51.7 ± 9.0 46.7 ± 8.0 < 0.001
Malnutrition at time of Diagnosis (PNI� <
45)
67 (23.3%) 30 (16.9%) 37 (33.9%) 0.001
PNI� at time of treatment initiation§ 49.1 ± 6.6 50.4 ± 5.7 46.9 ± 7.3 < 0.001




30 (16.9%) 37 (33.9%) < 0.001
Cavitary lesion on computed tomography 112 (36.6%) 76 (39.4%) 36 (31.9%) 0.219
AFB smear 0.944
Negative 243 (79.4%) 153 (79.3%) 90 (79.6%)
1+ or 2+ 45 (14.7%) 28 (14.5%) 17 (15.0%)
3+ or 4+ 18 (5.9%) 12 (6.2%) 6 (5.3%)
Symptoms
Cough 135 (44.1%) 80 (41.5%) 55 (48.7%) 0.234
Sputum 142 (46.4%) 88 (45.6%) 54 (47.8%) 0.723
Dyspnea 41 (13.4%) 20 (10.4%) 21 (18.6%) 0.055
Hemoptysis 59 (19.3%) 44 (22.8%) 15 (13.3%) 0.051
Fever 19 (6.2%) 10 (5.2%) 9 (8.0%) 0.337
Weakness 11 (3.6%) 6 (3.1%) 5 (4.4%) 0.542
Time from diagnosis to treatment, months 12.2 ± 21.4 10.5 ± 18.9 14.9 ± 24.8 0.095
Treatment medication
Macrolide 298 (97.4%) 187 (96.9%) 111 (98.2%) 0.715
Rifampin 299 (97.7%) 189 (97.9%) 110 (97.3%) 0.712
Ethambutol 294 (96.1%) 184 (95.3%) 110 (97.3%) 0.545
Isoniazid 9 (2.9%) 5 (2.6%) 4 (3.5%) 0.730
Fluoroquinolones 11 (3.6%) 6 (3.1%) 5 (4.4%) 0.542
Aminoglycosides 42 (13.7%) 31 (16.1%) 11 (9.7%) 0.168
Other 9 (2.9%) 7 (3.6%) 2 (1.8%) 0.493
Initial number of medications 0.472
� 2 7 (2.3%) 5 (2.6%) 2 (1.8%)
3 252 (82.4%) 155 (80.3%) 97 (85.8%)
� 4 47 (15.4%) 33 (17.1%) 14 (12.4%)
Duration of treatment, months 14.2 ± 10.1 19.5 ± 8.7 5.1 ± 3.9 < 0.001




113 / 177 (63.8%) 47 / 60 (78.3%) 0.040
(Continued)
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diagnosis or treatment initiation and showed higher culture conversion rates and mortality
rates during the follow up.
Table 3 shows the relationship between malnutrition and treatment intolerance in the logis-
tic regression models. When age (> 65 years), gender, symptoms of dyspnea, hemoptysis, and
malnutrition were included in the regression model, malnutrition (OR: 2.559, 95% confidence
interval [CI]: 1.414–4.634, P = 0.002) was significantly related to treatment intolerance.
Variables related to culture conversion
To evaluate the factors related to culture conversion, patients who received treatment longer
than a year and whose culture conversion data were available were stratified by culture conver-
sion (Table 4). Among the 193 patients who received treatment longer than 12 months, culture
conversion data were available for 177 patients. Among these 177 patients, culture conversion
was achieved in 113 patients (63.8%). Patients who failed culture conversion were more likely
to be male, have a shorter time span between diagnosis and treatment, have a lower BMI, and
be treated longer. However, malnutrition at the time of diagnosis or treatment initiation did
not significantly correlate with culture conversion.
S1 Table shows the relationship between malnutrition and culture conversion failure in the
multivariate logistic regression models. When age, gender, cavitary lesion on CT, AFB smear
result, time from diagnosis to treatment, and malnutrition at the time of treatment were
included in the regression model, malnutrition (OR: 1.288, 95% CI: 0.630–2.637, P = 0.488)
was not significantly related to culture conversion failure.
Table 2. (Continued)
Variables All (n = 306) Treatment longer than 12 months
(n = 193, 63.1%)
Treatment shorter than 12 months
(n = 113, 36.9%)
P-value
Death during follow-up 27 (8.8%) 11 (5.7%) 16 (14.2%) 0.020
Data are presented as number (%) for categorical variables and median (range) or mean ± standard deviation (SD) for continuous variables
List of Abbreviations: AFB, acid-fast bacilli
�PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (1000 cells/μL)
§PNI data at time of treatment initiation were available for 287 patients
‡Culture conversion data within 1 year after treatment were available for 237 patients
https://doi.org/10.1371/journal.pone.0232714.t002
Table 3. Multivariate logistic regression analyses for variables related to treatment intolerance.
Variables OR (95% CI) P-value
Age� 65 years 1.147 (0.677–1.942) 0.611
Gender, Male 0.820 (0.475–1.414) 0.475
Dyspnea 1.522 (0.738–3.139) 0.255
Hemoptysis 0.557 (0.284–1.094) 0.089
Malnutrition, treatment initiation (PNI� <45) 2.559 (1.414–4.634) 0.002
List of Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; AFB, acid-fast bacilli; PNI, prognostic
nutritional index
�PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (1000 cells/μL)
https://doi.org/10.1371/journal.pone.0232714.t003
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Table 4. Basic characteristics of Mycobacterium avium complex lung disease patients who received treatment longer than 12 months according to conversion
failure�.
Variables All (n = 177) Conversion achieved (n = 113) Conversion failure (n = 64) P-value
Age� 65 years 79 (44.6%) 47 (41.6%) 32 (50.0%) 0.345
Gender, male 74 (41.8%) 38 (33.6%) 36 (56.3%) 0.004
BMI, kg/m2 19.7 ± 3.0 19.9 ± 3.1 19.4 ± 2.8 0.301
Smoking, pack-years 34.6 ± 26.4 37.0 ± 32.4 32.6 ± 20.7 0.625
Time from diagnosis to treatment, months 10.6 ± 18.9 13.5 ± 22.2 5.4 ± 8.7 0.009
Comorbidities
Hypertension 51 (28.8%) 33 (29.2%) 18 (28.1%) 1.000
Diabetes 24 (13.6%) 18 (15.9%) 6 (9.4%) 0.260
Chronic liver disease 13 (7.3%) 7 (6.2%) 6 (9.4%) 0.550
Chronic kidney disease 6 (3.4%) 4 (3.5%) 2 (3.1%) 1.000
Cardiovascular disease 20 (11.3%) 10 (8.8%) 10 (15.6%) 0.217
Malignancy 45 (25.4%) 31 (27.4%) 14 (21.9%) 0.475
Laboratory test
PNI� at time of diagnosis 51.8 ± 9.2 52.9 ± 9.7 49.9 ± 6.6 0.033
Malnutrition at time of Diagnosis (PNI� < 45) 25 (14.1%) 12 (10.6%) 13 (20.3%) 0.114
PNI� at time of treatment initiation‡ 50.4 ± 5.7 50.7 ± 5.2 49.8 ± 6.6 0.351
Malnutrition at time of treatment start‡ (PNI < 45) 28 (15.8%) 14 (12.3%) 14 (21.9%) 0.079
Cavitary lesion on computed tomography 71 (40.1%) 39 (34.%) 32 (50.0%) 0.055
AFB smear 0.015
Negative 142 (80.2%) 98 (86.7%) 44 (68.8%)
1+ or 2+ 24 (13.6%) 10 (8.8%) 14 (21.9%)
3+ or 4+ 11 (6.2%) 5 (4.4%) 6 (9.4%)
Symptoms
Cough 75 (42.4%) 45 (39.8%) 30 (46.9%) 0.429
Sputum 80 (45.2%) 47 (41.6%) 33 (51.6%) 0.212
Dyspnea 20 (11.3%) 12 (10.6%) 8 (12.5%) 0.806
Hemoptysis 39 (22.0%) 23 (20.4%) 16 (25.0%) 0.572
Fever 10 (5.6%) 8 (7.1%) 2 (3.1%) 0.333
Weakness 6 (3.4%) 6 (5.3%) 0 (0.0%) 0.088
Treatment medication
Macrolide 173 (97.7%) 110 (97.3%) 63 (98.4%) 1.000
Rifampin 174 (98.3%) 111 (98.2%) 63 (98.4%) 1.000
Ethambutol 170 (96.0%) 111 (98.2%) 59 (92.2%) 0.100
Isoniazid 3 (1.7%) 3 (2.7%) 0 (0.0%) 0.554
Fluoroquinolones 6 (3.4%) 2 (1.8%) 4 (6.3%) 0.191
Aminoglycosides 29 (16.4%) 15 (13.3%) 14 (21.9%) 0.145
Other 4 (2.3%) 1 (0.9%) 3 (4.7%) 0.135
Initial number of medications 0.648
� 2 5 (2.8%) 3 (2.7%) 2 (3.1%)
3 142 (80.2%) 93 (82.3%) 49 (76.6%)
�4 30 (16.9%) 17 (15.0%) 13 (20.3%)
Duration of treatment, months 20.5 ± 9.8 16.9 ± 4.8 24.0 ± 11.3 <0.001
Data are presented as number (%) for categorical variables and median (range) or mean ± standard deviation (SD) for continuous variables
List of Abbreviations: PNI, prognostic nutritional index; BMI, body mass index; AFB, acid-fast bacilli
�PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (/mm3)
§Among the 193 patients who received treatment longer than 12 months, culture conversion data were available for 177 patients
‡Among the 193 patients who received treatment longer than 12 months, PNI data at the time of treatment initiation were available for 178 patients
https://doi.org/10.1371/journal.pone.0232714.t004
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Variables related to all-cause mortality
Kaplan-Meier survival curves stratified by malnutrition and non-malnutrition groups at the
time of diagnosis are shown in Fig 2. Patients in the malnutrition group exhibited a signifi-
cantly higher mortality rate (P < 0.001) than those in the non-malnutrition group. The rela-
tionships between all-cause mortality and clinical parameters, including malnutrition, were
evaluated in Table 5. Univariate analysis revealed that age� 65 years, male gender, lower BMI,
malnutrition at the time of diagnosis (P < 0.001), treatment shorter than 12 months, and his-
tory of diabetes, chronic kidney disease, cardiovascular disease, and cancer were correlated
significantly with all-cause mortality. Comparison of the contributions of these indices by
multivariate Cox proportional hazards analyses demonstrates that malnutrition (hazard ratio:
2.755, 95% CI: 1.610–4.475, P< 0.001), age� 65 years, male gender, lower BMI, history of
cancer, and positive AFB smear were significant risk factors for all-cause mortality.
Fig 2. Kaplan–Meier survival curves stratified by nutritional status. Patients were divided into malnutrition and non-malnutrition groups according
to prognostic nutritional index�. �Cut-off value of prognostic nutritional index for defining malnutrition and non-malnutrition was 45. List of
Abbreviations; MAC, Mycobacterium avium complex.
https://doi.org/10.1371/journal.pone.0232714.g002
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Discussion
Poor nutritional status represented by low BMI, low fat composition, and low level of serum
albumin were reported as risk factors of progression of NTM PD. [25–27] Thus, experts rec-
ommend the treatment of MAC-PD when patients with considerable burden of disease (e.g.,
cavitary lesion on chest CT, AFB smear positive) have a poor nutritional status. However, the
impact of poor nutritional status on the treatment outcome of MAC-PD has not been well
evaluated.
To our knowledge, this is the first study to demonstrate the clinical utility of analyzing the
relationship between PNI (as a composite value of malnutrition) and outcomes of MAC-PD.
All-cause mortality was significantly higher in the malnutrition group than in the non-malnu-
trition group as defined by PNI at the time of diagnosis. Treatment intolerance, but not culture
conversion rates after antibiotic therapy, was also related with malnutrition as defined by PNI
at the time of treatment initiation. In addition, symptoms such as dyspnea, fever, and weakness
were more common in patients with malnutrition than those in the non-malnutrition group.
This may explain the relationship between malnutrition and treatment intolerance and mor-
tality, as well as quality of life.
In this study, patients were divided into malnutrition and non-malnutrition groups accord-
ing to the cut-off PNI score of 45, which has been reported to indicate moderate-to-severe mal-
nutrition. [24] Conversely, in previous studies, the PNI cut-off value for defining malnutrition
Table 5. Univariate and multivariate Cox’s proportional hazard analyses of factors for mortality in Mycobacterium avium complex lung disease patients.
Variables Among the deaths (n = 63) Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Age, years 69.6 ± 10.7 1.060 (1.033–1.086) <0.001
Age� 65 years 46 (73.0%) 2.960 (1.692–5.179) <0.001 2.044 (1.075–3.887) 0.029
Sex, male 46 (73.0%) 3.792 (2.170–6.626) <0.001 2.534 (1.376–4.664) 0.003
Body mass index, kg/m2 19.0 ± 3.6 0.854 (0.786–0.927) <0.001 0.858 (0.786–0.937) 0.001
Smoking, pack-years 32.2 ± 19.3 1.006 (0.990–1.023) 0.465
NTM type, with cavity 18 (28.6%) 1.299 (0.751–2.248) 0.349
AFB smear
Negative 43 (68.3%) Reference Reference
1+ or 2+ 14 (22.2%) 3.151 (1.705–5.822) <0.001 2.849 (1.493–5.437) 0.001
3+ or 4+ 6 (9.5%) 2.380 (0.981–5.775) 0.055 2.477 (0.999–6.139) 0.050
Malnutrition, Diagnosis (PNI < 45) 29 (46.0%) 4.421 (2.686–7.277) <0.001 2.755 (1.610–4.715) <0.001
PNI, diagnosis 44.5 ± 10.4 0.906 (0.880–0.932) <0.001
Treatment started 27 (42.9%) 0.644 (0.388–1.071) 0.090 0.496 (0.288–0.854) 0.011
Treatment longer than 12 months 11 (17.5%) 0.356 (0.185–0.686) 0.002
Treatment duration, months 10.7 ± 8.2 0.941 (0.896–0.989) 0.016
Time from diagnosis to treatment, months 6.9 ± 20 1.009 (0.979–1.039) 0.576
Hypertension 30 (47.6%) 1.560 (0.951–2.560) 0.078 1.140 (0.629–2.067) 0.665
Diabetes 16 (25.4%) 1.950 (1.105–3.441) 0.021 1.348 (0.723–2.514) 0.347
Chronic liver disease 2 (3.2%) 0.410 (0.100–1.678) 0.215
Chronic kidney disease 6 (9.5%) 2.209 (0.950–5.140) 0.066 1.701 (0.685–4.227) 0.253
Cardiovascular disease 16 (25.4%) 1.987 (1.121–3.520) 0.019 1.363 (0.718–2.590) 0.344
Cancer 31 (49.2%) 2.841 (1.731–4.664) <0.001 2.477 (0.999–6.139) 0.001
List of Abbreviations: HR, hazards ratio; 95% CI, 95% confidence interval; BMI, body mass index; PNI, prognostic nutritional index;
�PNI = 10 × serum albumin value (g/dL) + 0.005 × total lymphocyte count in the peripheral blood (1000 cells/μL)
https://doi.org/10.1371/journal.pone.0232714.t005
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varied between 40.0 and 50.0. [28–30] The optimal cut-off value and the division of the groups
by PNI remain unclear. Further studies including prospective studies are needed to clarify the
cut-off point not only for MAC-PD patients but for general non-surgical patients.
Numerous indicators have been used as markers to reflect nutritional status. Nutritional
risk screening [5] uses information regarding food intake, BMI, and weight loss. Subjective
global assessment [6] is a more detailed assessment that comprises patient history, as well as
physical and subjective global assessment-specified variables. BMI is a well-known nutritional
indicator; however, BMI distribution differs greatly across racial and ethnic populations. The
nutritional status score [31] is calculated using serum cholesterol, lymphocyte, and albumin,
and the Glasgow prognostic score [32] is calculated using albumin and C-reactive protein. In
comparison, as mentioned before, PNI is calculated using only serum albumin levels and lym-
phocyte counts. PNI is therefore an easy and reliable tool with minor variability. [33]
PNI is known to reflect the nutritional and immune condition of patients. [23] Malnutri-
tion reduces albumin concentration by decreasing its rate of synthesis; similarly, inflammation
increases fractional catabolic rate, and in severe circumstances, it increases the permeability of
vasculature, thereby allowing albumin to leak out into the extravascular space. [34] Further-
more, Siedner et al. reported that low serum albumin levels were strongly correlated with
higher levels of the inflammatory marker interleukin 6, thus possibly indicating that low albu-
min levels might be a consequence of immune activation through mechanisms less directly
associated with interleukin 6. [35] Malnutrition also results in lymphocyte deficiency. Chandra
et al. [36] reported that patients with malnutrition had reduced lymphocyte counts. Lympho-
cytes are important to humoral immunity as well as cell-mediated immunity. [37, 38]
Malnutrition is reported to be risk factor of progression of NTM-PD, [25–27] and the out-
come of mycobacterial infections is dependent on the interaction between the bacteria and the
host’s immune system. [39] Considering that PNI reflects both nutritional and immune status,
low PNI scores could act as risk factors for the progression of MAC-PD. PNI scores may
decrease because of advanced inflammation of MAC-PD and thus be related with higher
mortality.
Treatment intolerance is particularly important in the treatment of MAC-PD. In the exist-
ing guideline, considerations on whether to start treatment, the age, baseline disease status,
and risk benefit assessment of treatment effect and side effect are essential. In our study, one
third of patients who initiated multiple antibiotics treatment discontinued the medication, as
previously reported. [17] PNI was meaningful in predicting drug intolerance in our study.
Further consideration of PNI may help predict drug intolerance and manage patients with
MAC-PD.
Previous studies have demonstrated that nutritional interventions can improve a
patient’s lymphocyte [36] and albumin levels. [40] Nutritional support, therefore, may result
in higher PNI scores. As our study demonstrated that higher PNI scores are related with bet-
ter outcomes, nutritional interventions for MAC-PD might be helpful for patients with low
PNI scores.
This study has some limitations. First, the study was retrospective and only included sam-
ples from a single center with limited number of patients and involved no replication cohort.
Although multivariate analyses were performed, there are many compounding factors that
influence the treatment and prognosis of MAC-PD. However, the validity of reported prog-
nostic factors, such as BMI, and history of cancer or diabetes, was confirmed in this study
population, thereby lending support to the present findings. Secondly, other methods of evalu-
ating malnutrition other than BMI were not available at the time of our analysis. Integrating
and comparing other indexes in future studies may help to further comprehend the nature
and prognosis of MAC-PD. Thirdly, although PNI has been proposed as a simple surrogate
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marker for evaluating immune-nutritional status, serum albumin levels and lymphocyte
counts could also be influenced by a number of other factors, including medications, underly-
ing disease, time, and age. [1]
Conclusion
In the present study, we found that malnutrition, as defined by PNI, is a risk factor for all-
cause mortality in MAC-PD patients. Treatment intolerance during antibiotic therapy was sig-
nificantly higher in patients with malnutrition than in those in the non-malnutrition group.
These findings suggest that the PNI score, which can be easily calculated using serum albumin
levels and lymphocyte counts, is a useful prognostic marker for mortality and treatment intol-
erance. It is important to stress the importance of nutritional assessment for patients with
MAC-PD.
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